Development asset linked to Jiangsu Alphamab Biopharmaceuticals in public FDA and regional records. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
biotech · Esophageal Squamous Cell Carcinoma
Jiangsu Alphamab Biopharmaceuticals
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Jiangsu Alphamab Biopharmaceuticals drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Jiangsu Alphamab Biopharmaceuticals pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Jiangsu Alphamab Biopharmaceuticals drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.